major thalassemia. Beta thalassemia
Conditions
Interventions
Intervention 1: Intervention group 1: In this group, patients with hypogonadism took Bisphosphonate (Alendronate, manufactured by Alborz Daro Company, Iran) for one year and one tablet at a dose of 70
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients Consent to participate in the study Male patients with major thalassemia and older than 13.5 years Patients with hypogonadism (based on blood testosterone, LH and FSH levels) and without hypogonadism No concomitant underlying disease (including thyroid disease, parathyroid disease, kidney and liver disease and diabetes)
Exclusion criteria
Exclusion criteria: Patients with abnormal level of liver enzymes (AST and ALT) Patients with renal disorder Patients with abnormal levels of calcium, blood phosphorus and vitamin D3 Patients with abnormal levels of thyroid function hormones and diabetes Patients with abnormal levels of PTH and ALP Patients with bone density greater than -5.2 Do not take the drug by the patient until the end of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone density. Timepoint: At the beginning of the study and one year after the intervention. Method of measurement: Bone mineral density (BMD) test by DEXA method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDavod Amirkashani
Iran University of Medical Sciences
Outcome results
None listed